SNG001

About Synairgen

Synairgen is a clinical-stage biotech focused on developing inhaled interferon beta (SNG001) as a broad-spectrum, host-directed antiviral for severe respiratory infections. Founded on pioneering academic research into lung immunology, the company has advanced SNG001 through multiple clinical trials, including during the COVID-19 pandemic, demonstrating proof-of-concept. Its current strategy is to target the high-mortality, underserved population of mechanically ventilated patients in intensive care through a Phase 2 trial (INVENT), leveraging a novel mechanism of action that is agnostic to the specific virus.

About Synairgen

Synairgen is a clinical-stage biotech focused on developing inhaled interferon beta (SNG001) as a broad-spectrum, host-directed antiviral for severe respiratory infections. Founded on pioneering academic research into lung immunology, the company has advanced SNG001 through multiple clinical trials, including during the COVID-19 pandemic, demonstrating proof-of-concept. Its current strategy is to target the high-mortality, underserved population of mechanically ventilated patients in intensive care through a Phase 2 trial (INVENT), leveraging a novel mechanism of action that is agnostic to the specific virus.

About Synairgen

Synairgen is a clinical-stage biotech focused on developing inhaled interferon beta (SNG001) as a broad-spectrum, host-directed antiviral for severe respiratory infections. Founded on pioneering academic research into lung immunology, the company has advanced SNG001 through multiple clinical trials, including during the COVID-19 pandemic, demonstrating proof-of-concept. Its current strategy is to target the high-mortality, underserved population of mechanically ventilated patients in intensive care through a Phase 2 trial (INVENT), leveraging a novel mechanism of action that is agnostic to the specific virus.

Therapeutic Areas